UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
28
August 2025 - Transaction in Own Shares
|
99.1
Haleon plc: Transaction
in own shares
28 August 2025: Haleon plc (the "Company" or "Haleon")
today announces the purchase of 2,875,831 ordinary shares of
£0.01 each in the Company (the "Shares") for
cancellation under the second tranche of its share buyback
programme announced on 31 July 2025.
|
|
London Stock Exchange
|
CBOE (UK)/BXE
|
CBOE (UK)/CXE
|
|
Date of
purchase:
|
27
August 2025
|
27
August 2025
|
27
August 2025
|
|
Number
of Shares purchased:
|
2,875,831
|
-
|
-
|
|
Highest
price paid per Share (p):
|
363.7000
|
-
|
-
|
|
Lowest
price paid per Share (p):
|
359.2000
|
-
|
-
|
|
Volume
weighted average price paid per Share (p):
|
361.3796
|
-
|
-
|
Following
the settlement of the above, the Company's registered share
capital is 8,963,475,311 ordinary shares
of £0.01 each, of which 3,880,205 are held as
treasury shares. Therefore, the number of ordinary shares with
voting rights is 8,959,595,106 and this figure may be used by
shareholders to determine if they are required to notify their
interest, or a change to their interest, in Haleon under the FCA's
Disclosure Guidance and Transparency Rules.
In
accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as
it applies in the UK (the Market Abuse Regulation), a
full breakdown of the individual trades is available at the link
below:
http://www.rns-pdf.londonstockexchange.com/rns/9460W_1-2025-8-27.pdf
This
announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any
jurisdiction.
This
announcement and individual trade breakdown will also be available
on the Company's website at: www.haleon.com/investors.
|
Enquiries
|
|
||
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44
7894 505730
|
|
Email: [email protected]
|
Email: [email protected]
|
||
About Haleon
Haleon
(LSE/NYSE: HLN) is a global leader in consumer health, with a
purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax,
Polident, Sensodyne, Theraflu and Voltaren - are built on trusted
science, innovation and deep human understanding.
For
more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date: August 28, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|